$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

$lsta Overview Financials Valuation SEC Filings Company Website

2012 Q3 Form 10-Q Financial Statement

#000144530512002636 Filed on August 14, 2012

Income Statement

Concept	2012 Q3	2012 Q2	2011 Q2
Revenue	$4.434M	$3.372M	$2.211M
YoY Change	103.67%	52.53%	-88.61%
Cost Of Revenue	$3.747M	$2.736M	$1.791M
YoY Change	98.14%	52.79%	-86.13%
Gross Profit	$686.5K	$636.1K	$420.1K
YoY Change	140.29%	51.42%	-93.54%
Gross Profit Margin	15.48%	18.86%	19.0%
Selling, General & Admin	$5.947M	$4.733M	$8.869M
YoY Change	-0.48%	-46.63%	12.69%
% of Gross Profit	866.35%	744.05%	2111.13%
Research & Development	$2.828M	$2.715M	$1.591M
YoY Change	83.6%	70.58%	-25.29%
% of Gross Profit	411.99%	426.75%	378.81%
Depreciation & Amortization	$390.0K	$380.0K	-$1.280M
YoY Change	30.0%	-129.69%	-282.86%
% of Gross Profit	56.81%	59.74%	-304.7%
Operating Expenses	$8.775M	$7.448M	$10.46M
YoY Change	16.76%	-28.8%	4.6%
Operating Profit	-$8.089M	-$6.811M	-$10.04M
YoY Change	11.87%	-32.16%	186.85%
Interest Expense	$384.2K	$450.9K	$705.9K
YoY Change	-39.29%	-36.13%	-7159.44%
% of Operating Profit
Other Income/Expense, Net	-$459.0K	-$426.6K	-$150.2K
YoY Change	-169.55%	183.95%	-200.15%
Pretax Income	-$8.548M	-$7.238M	-$10.19M
YoY Change	30.11%	-28.97%	203.28%
Income Tax	$0.00	$0.00	-$103.7K
% Of Pretax Income
Net Earnings	-$8.411M	-$20.51M	-$10.61M
YoY Change	14.49%	93.34%	97.5%
Net Earnings / Revenue	-189.69%	-608.09%	-479.72%
Basic Earnings Per Share
Diluted Earnings Per Share	-$5.682M	-$15.31M	-$15.61M
COMMON SHARES
Basic Shares Outstanding	152.5M shares	132.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2012 Q3	2012 Q2	2011 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.400M	$2.100M	$4.900M
YoY Change	-53.85%	-57.14%	-56.64%
Cash & Equivalents	$5.391M	$2.113M	$1.975M
Short-Term Investments			$0.00
Other Short-Term Assets	$40.20M	$47.70M	$6.200M
YoY Change	957.89%	669.35%	21.57%
Inventory	$448.0K	$1.161M	$25.00M
Prepaid Expenses
Receivables	$1.795M	$1.257M	$7.400M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$47.89M	$52.25M	$43.40M
YoY Change	6.18%	20.4%	11.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.07M	$11.30M	$50.30M
YoY Change	-77.69%	-77.53%	66.56%
Goodwill	$11.12M	$11.12M
YoY Change
Intangibles	$14.63M	$14.78M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$932.5K	$3.507M	$3.400M
YoY Change	-83.35%	3.15%	1033.33%
Total Long-Term Assets	$80.92M	$85.77M	$126.9M
YoY Change	-34.26%	-32.41%	49.29%
TOTAL ASSETS
Total Short-Term Assets	$47.89M	$52.25M	$43.40M
Total Long-Term Assets	$80.92M	$85.77M	$126.9M
Total Assets	$128.8M	$138.0M	$170.3M
YoY Change	-23.42%	-18.95%	37.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.571M	$2.171M	$9.300M
YoY Change	-74.03%	-76.65%	-1.06%
Accrued Expenses	$1.386M	$2.109M	$4.900M
YoY Change	-76.52%	-56.97%	58.06%
Deferred Revenue
YoY Change
Short-Term Debt	$3.500M	$3.500M	$7.900M
YoY Change	-56.25%	-55.7%
Long-Term Debt Due	$100.0K	$200.0K	$11.10M
YoY Change	-97.37%	-98.2%	1.83%
Total Short-Term Liabilities	$50.44M	$48.02M	$38.80M
YoY Change	60.11%	23.75%	45.32%
LONG-TERM LIABILITIES
Long-Term Debt	$2.800M	$3.600M	$5.900M
YoY Change	-49.09%	-38.98%
Other Long-Term Liabilities	$139.3K	$70.53K	$26.10M
YoY Change	-99.45%	-99.73%	222.22%
Total Long-Term Liabilities	$21.94M	$34.58M	$32.00M
YoY Change	-28.29%	8.06%	295.06%
TOTAL LIABILITIES
Total Short-Term Liabilities	$50.44M	$48.02M	$38.80M
Total Long-Term Liabilities	$21.94M	$34.58M	$32.00M
Total Liabilities	$72.38M	$82.59M	$107.8M
YoY Change	-23.57%	-23.38%	41.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$181.6M	-$173.1M
YoY Change
Common Stock	$155.1K	$137.6K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$48.21M	$46.35M	$62.50M
YoY Change
Total Liabilities & Shareholders Equity	$128.8M	$138.0M	$170.3M
YoY Change	-23.42%	-18.95%	37.56%

Cashflow Statement

Concept	2012 Q3	2012 Q2	2011 Q2
OPERATING ACTIVITIES
Net Income	-$8.411M	-$20.51M	-$10.61M
YoY Change	14.49%	93.34%	97.5%
Depreciation, Depletion And Amortization	$390.0K	$380.0K	-$1.280M
YoY Change	30.0%	-129.69%	-282.86%
Cash From Operating Activities	-$3.380M	-$2.960M	-$3.070M
YoY Change	-20.47%	-3.58%	248.86%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	-$50.00K	$320.0K
YoY Change	-83.33%	-115.63%	-106.57%
Acquisitions
YoY Change
Other Investing Activities	-$350.0K	-$2.160M	-$3.630M
YoY Change	-110.26%	-40.5%	-348.63%
Cash From Investing Activities	-$370.0K	-$2.210M	-$3.320M
YoY Change	-111.25%	-33.43%	-2.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.690M	1.540M	1.770M
YoY Change	-77.97%	-12.99%	-52.67%
NET CHANGE
Cash From Operating Activities	-3.380M	-2.960M	-3.070M
Cash From Investing Activities	-370.0K	-2.210M	-3.320M
Cash From Financing Activities	1.690M	1.540M	1.770M
Net Change In Cash	-2.060M	-3.630M	-4.620M
YoY Change	-130.7%	-21.43%	740.0%
FREE CASH FLOW
Cash From Operating Activities	-$3.380M	-$2.960M	-$3.070M
Capital Expenditures	-$20.00K	-$50.00K	$320.0K
Free Cash Flow	-$3.360M	-$2.910M	-$3.390M
YoY Change	-18.64%	-14.16%	-184.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2011Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	1177.1	USD
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2287201	USD
CY2012Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2171484	USD
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1010475	USD
CY2012Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1256640	USD
CY2012Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2108522	USD
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1090176	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4152343	USD
CY2012Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4174332	USD
	us-gaap	Additional Information About Entitys Reportable Segments AdditionalInformationAboutEntitysReportableSegments	three reportable segments
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	200858638	USD
CY2012Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	215184988	USD
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1086400	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6657000	USD
CY2011Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4745600	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3555000	USD
CY2012Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	448487	USD
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	187600	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	872736	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1329187	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	17600	USD
CY2012Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	151300	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	302600	USD
CY2011Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8800	USD
CY2011Q4	us-gaap	Assets Assets	155327780	USD
CY2012Q2	us-gaap	Assets Assets	138026183	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	38610336	USD
CY2012Q2	us-gaap	Assets Current AssetsCurrent	52252104	USD
CY2012Q2	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	46838739	USD
CY2011Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	32367217	USD
CY2011Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Noncurrent AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	75570645	USD
CY2012Q2	us-gaap	Assets Of Disposal Group Including Discontinued Operation Noncurrent AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	45063647	USD
CY2012Q2	us-gaap	Business Acquisition Contingent Consideration At Fair Value Noncurrent BusinessAcquisitionContingentConsiderationAtFairValueNoncurrent	3130000	USD
CY2011Q4	us-gaap	Business Acquisition Contingent Consideration At Fair Value Noncurrent BusinessAcquisitionContingentConsiderationAtFairValueNoncurrent	3130000	USD
CY2011Q4	us-gaap	Cash Cash	92.9	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	227942	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3935160	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2112582	USD
CY2011Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1975178	USD
CY2011Q2	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	4850410	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	15612391	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	12745432	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value Including Discontinued Operations CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations	18261770	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5516338	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10761981	USD
CY2012Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	600000	USD
CY2011Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	800000	USD
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	6083610	USD
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	229176	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-2140792	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-6256240	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	8992032	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-4137269	USD
CY2012Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	1.85
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	7352649	shares
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2012Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2012Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	137619903	shares
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	109329587	shares
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	109329587	shares
CY2012Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	137619903	shares
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	109330	USD
CY2012Q2	us-gaap	Common Stock Value CommonStockValue	137620	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20706054	USD
CY2011Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11312129	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29831477	USD
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20657183	USD
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-12900144	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-12600875	USD
CY2011Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-655226	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	556611	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-20149443	USD
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-33557327	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-42432352	USD
CY2011Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-11967355	USD
CY2012Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1	shares
CY2011Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1	shares
	us-gaap	Cost Of Revenue CostOfRevenue	5691696	USD
CY2011Q2	us-gaap	Cost Of Revenue CostOfRevenue	1790729	USD
	us-gaap	Cost Of Revenue CostOfRevenue	3460892	USD
CY2012Q2	us-gaap	Cost Of Revenue CostOfRevenue	2735990	USD
	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.05
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-178770	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2012Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1631480	USD
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1121134	USD
CY2012Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	156466	USD
CY2011Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	169198	USD
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	25994800	USD
CY2012Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	3774655	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	3774655	USD
CY2011Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	3774.7	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	922975	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	774773	USD
CY2011Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	474463	USD
CY2012Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	362946	USD
CY2011Q2	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	2875232	USD
CY2012Q2	us-gaap	Disposal Group Including Discontinued Operation Cash And Cash Equivalents DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents	16149188	USD
CY2011Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	340.4	USD
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2011Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	70582	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-41506	USD
CY2009Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.51
CY2012Q2	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.51
CY2012Q2	us-gaap	Escrow Deposit EscrowDeposit	2500000	USD
CY2012Q2	us-gaap	Fair Value Liabilities Measured On Recurring Basis Debt Instrument Valuation Techniques FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniques	The fair value of contingent consideration obligations is based on a discounted cash flow model using a probability-weighted income approach
CY2012Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-986000	USD
CY2011Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-683000	USD
CY2012Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15769000	USD
CY2011Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15769000	USD
CY2011Q4	us-gaap	Goodwill Goodwill	11117770	USD
CY2011Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	15086000	USD
CY2012Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14783000	USD
CY2012Q2	us-gaap	Goodwill Goodwill	11117770	USD
CY2011Q4	us-gaap	Goodwill Goodwill	4104.5	USD
	us-gaap	Gross Profit GrossProfit	1453133	USD
	us-gaap	Gross Profit GrossProfit	199073	USD
CY2011Q2	us-gaap	Gross Profit GrossProfit	420089	USD
CY2012Q2	us-gaap	Gross Profit GrossProfit	636107	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-15028380	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-20001720	USD
CY2011Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-10071784	USD
CY2012Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-7151023	USD
	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-188722	USD
CY2011Q2	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-14598	USD
	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-201905	USD
CY2012Q2	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	-86961	USD
CY2011Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-10190102	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-20382395	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-15217102	USD
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-7237984	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-15217102	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-20203625	USD
CY2011Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-10086382	USD
CY2012Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-7237984	USD
CY2011Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.13
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.26
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.12
CY2012Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.05
CY2011Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-451510	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-27412679	USD
CY2012Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-26184931	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-34024	USD
CY2011Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	82473	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	-12587593	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	743013	USD
CY2012Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	-12830618	USD
CY2012Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-13354313	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-14825086	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-777037	USD
CY2011Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-533983	USD
CY2011Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.01
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.01
CY2012Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.10
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.12
	us-gaap	Income Taxes Paid IncomeTaxesPaid	811500	USD
CY2011Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-103720	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2012Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-178770	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1634500	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	459809	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	524115	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	497613	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1153447	USD
CY2012Q2	us-gaap	Increase Decrease In Fair Value Of Interest Rate Fair Value Hedging Instruments IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments	-52100	USD
	us-gaap	Increase Decrease In Fair Value Of Interest Rate Fair Value Hedging Instruments IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments	-128500	USD
	us-gaap	Increase Decrease In Fair Value Of Interest Rate Fair Value Hedging Instruments IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments	17000	USD
CY2011Q2	us-gaap	Increase Decrease In Fair Value Of Interest Rate Fair Value Hedging Instruments IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments	27900	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	513598	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	810728	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-97248	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	180000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	195927	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-187687	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	500	USD
CY2012Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	14783433	USD
CY2011Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	15086038	USD
	us-gaap	Interest Expense InterestExpense	1427231	USD
	us-gaap	Interest Expense InterestExpense	975020	USD
CY2012Q2	us-gaap	Interest Expense InterestExpense	450904	USD
CY2011Q2	us-gaap	Interest Expense InterestExpense	705944	USD
	us-gaap	Interest Paid InterestPaid	1333800	USD
	us-gaap	Interest Paid InterestPaid	1243700	USD
	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	212000	USD
	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	106400	USD
CY2012Q2	us-gaap	Inventory Net InventoryNet	1161343	USD
CY2011Q4	us-gaap	Inventory Net InventoryNet	647745	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	6656953	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	3555011	USD
CY2012Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	435400	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	848200	USD
CY2011Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	528900	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	941500	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	155327780	USD
CY2012Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	138026183	USD
CY2012Q2	us-gaap	Liabilities Current LiabilitiesCurrent	48015270	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36446644	USD
CY2012Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	34577911	USD
CY2011Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	33937292	USD
CY2011Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	28165010	USD
CY2012Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	38407500	USD
CY2012Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	27026259	USD
CY2011Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	26388976	USD
CY2011Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2012Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	57057	USD
CY2011Q4	us-gaap	Minority Interest MinorityInterest	18106961	USD
CY2012Q2	us-gaap	Minority Interest MinorityInterest	5506086	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 1  – The Business</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem, Inc. (“NeoStem” or the “Company”) was incorporated under the laws of the State of Delaware in September 1980 under the name Fidelity Medical Services, Inc. The Company’s corporate headquarters are located at 420 Lexington Avenue, Suite 450, New York, NY 10170. The Company’s telephone number is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">(212) 584-4180</font><font style="font-family:inherit;font-size:10pt;"> and its website address is </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">www.neostem.com</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem, Inc. is a cellular therapy company. In 2011, we operated our business in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three reportable segments</font><font style="font-family:inherit;font-size:10pt;">: (i) Cell Therapy — United States; (ii) Regenerative Medicine — China; and (iii) Pharmaceutical Manufacturing — China. Effective March 31, 2012, we no longer operated in the Regenerative Medicine – China reportable segment, which is now reported in discontinued operations (see Note 13). On June 18, 2012, we also announced an agreement to sell our </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">51%</font><font style="font-family:inherit;font-size:10pt;"> interest in Suzhou Erye, which represented the operations in our Pharmaceutical Manufacturing - China segment, and is also reported in discontinued operations (see Note 13). As a result, the Company currently operates in a single reporting segment - Cell Therapy. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is rapidly emerging as a technology and market leading company in the fast developing cell therapy market. The Company's multifaceted business strategy combines a state-of-the-art contract development and manufacturing organization (CDMO) with a medically important cell therapy product development program enabling short-term and long-term revenue growth opportunities. The Company's service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a dynamic patent and patent pending (IP) portfolio, we are well positioned to succeed.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2012</font><font style="font-family:inherit;font-size:10pt;"> and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2011</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2010</font><font style="font-family:inherit;font-size:10pt;"> included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2011</font><font style="font-family:inherit;font-size:10pt;">. Operating results for the three and six month periods ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2012</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the year ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2012</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of NeoStem, Inc. and its wholly owned and partially owned subsidiaries and affiliates as listed below:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="41%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="32%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="25%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Entity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Percentage of Ownership</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Location</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Parent  Company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem Therapies, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stem Cell Technologies, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amorcyte, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CBH Acquisition LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">China Biopharmaceuticals Holdings, Inc. (CBH)  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100% owned by CBH Acquisition LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Suzhou Erye Pharmaceuticals Company Ltd. (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51% owned by CBH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">People’s Republic of China</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Progenitor Cell Therapy, LLC (PCT)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NeoStem Family Storage, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100% owned by PCT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Athelos Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80.1% owned by PCT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PCT Allendale, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100% owned by PCT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States of America</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Represents the operations of our former Pharmaceutical Manufacturing - China reporting segment, which was discontinued on June 18, 2012, and is currently reported in discontinued operations.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Joint Venture Agreement that governs the ownership and management of Erye provides, through 2012: (i) </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">49%</font><font style="font-family:inherit;font-size:10pt;"> of undistributed profits (after tax) would be distributed to Suzhou Erye Economy and Trading Co Ltd. (“EET”), the owner of the remaining </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">49%</font><font style="font-family:inherit;font-size:10pt;"> interest in Erye and loaned back to Erye for use in connection with its construction of the new Erye facility (to be repaid gradually after construction is completed); (ii) </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">45%</font><font style="font-family:inherit;font-size:10pt;"> of the net profit after tax due to the Company would be provided to Erye as part of the new facility construction fund, which will be characterized as paid-in capital for our </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">51%</font><font style="font-family:inherit;font-size:10pt;"> interest in Erye; and (iii) only </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6%</font><font style="font-family:inherit;font-size:10pt;"> of the net profit would be distributed to us directly for our operating expenses (see Note 13). On June 18, 2012, the Company signed a definitive agreement to sell its </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">51%</font><font style="font-family:inherit;font-size:10pt;"> interest in Erye. The definitive agreement provides that payment to us of the purchase consideration shall satisfy and discharge in full Erye's obligations with respect to any dividends which the Company might be entitled to. The closing of the transaction is subject to the satisfaction of certain conditions.</font></div></div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8849663	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8726993	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	8497817	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2766053	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6416706	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2316803	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-160466	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-176011	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13265520	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-852346	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9844378	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9128251	USD
	us-gaap	Net Income Loss NetIncomeLoss	-29853466	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-20505336	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20778757	USD
CY2011Q2	us-gaap	Net Income Loss NetIncomeLoss	-10605767	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-30049701	USD
CY2011Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10776549	USD
CY2012Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20593727	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21136172	USD
	us-gaap	Noncash Contribution Expense NoncashContributionExpense	0	USD
	us-gaap	Noncash Contribution Expense NoncashContributionExpense	607363	USD
CY2012Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-426551	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-863214	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1147336	USD
CY2011Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-150222	USD
CY2012Q2	us-gaap	Notes Payable NotesPayable	212000	USD
CY2011Q4	us-gaap	Notes Payable NotesPayable	148100	USD
CY2011Q4	us-gaap	Notes Payable Current NotesPayableCurrent	148062	USD
CY2012Q2	us-gaap	Notes Payable Current NotesPayableCurrent	154978	USD
CY2011Q2	us-gaap	Operating Expenses OperatingExpenses	10459969	USD
	us-gaap	Operating Expenses OperatingExpenses	15807021	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	7447540	USD
	us-gaap	Operating Expenses OperatingExpenses	19434132	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14353888	USD
CY2011Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10039880	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19235059	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6811433	USD
CY2012Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3725300	USD
CY2012Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	685700	USD
CY2012Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	563900	USD
CY2012Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	566100	USD
CY2012Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	624200	USD
CY2012Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	992200	USD
CY2012Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	293200	USD
CY2012Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	27000	USD
CY2011Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	47427300	USD
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3326938	USD
CY2012Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3507266	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Period Increase Decrease OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease	197429	USD
CY2012Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	35581	USD
CY2011Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1429463	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	367422	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	88206	USD
CY2012Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Period Increase Decrease OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease	-134412	USD
CY2011Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Period Increase Decrease OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease	-1429463	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Period Increase Decrease OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease	197429	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Period Increase Decrease OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease	88206	USD
	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	0	USD
CY2011Q2	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	-169993	USD
CY2012Q2	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	-169993	USD
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2012Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	70528	USD
CY2012Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	24353	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	279895	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	111806	USD
CY2011Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	555722	USD
	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	0	USD
	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	1391926	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	31702	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	387908	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	176011	USD
CY2012Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	88391	USD
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	196235	USD
CY2011Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	170782	USD
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	357415	USD
CY2012Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	88391	USD
CY2011Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	170782	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	357415	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	196235	USD
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2010Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2012Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000	shares
CY2012Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	10000	shares
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue	100	USD
CY2012Q2	us-gaap	Preferred Stock Value PreferredStockValue	100	USD
CY2012Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	882800	USD
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	649739	USD
CY2011Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	178.2	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	9951227	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	5907723	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	223433	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	149766	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7100	USD
	us-gaap	Profit Loss ProfitLoss	-42629781	USD
	us-gaap	Profit Loss ProfitLoss	-20237649	USD
CY2012Q2	us-gaap	Profit Loss ProfitLoss	-33422915	USD
CY2011Q2	us-gaap	Profit Loss ProfitLoss	-10537892	USD
CY2012Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11301963	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11616053	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	159460	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	234170	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	3000000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	93755	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	64366	USD
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2714587	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4116434	USD
CY2011Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1591354	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4661792	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	927000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2012Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-173144555	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-143094854	USD
	us-gaap	Revenues Revenues	3659965	USD
	us-gaap	Revenues Revenues	7144829	USD
CY2011Q2	us-gaap	Revenues Revenues	2210818	USD
CY2012Q2	us-gaap	Revenues Revenues	3372097	USD
	us-gaap	Sale Of Stock Percentage Of Ownership Before Transaction SaleOfStockPercentageOfOwnershipBeforeTransaction	0.51
CY2010Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.945
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9951227	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3555011	USD
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	46352485	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	62025557	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	80132518	USD
CY2012Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	51858571	USD
CY2012Q2	us-gaap	Temporary Equity Liquidation Preference Per Share TemporaryEquityLiquidationPreferencePerShare	1.00
CY2011Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	3635061	USD
CY2012Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	3541306	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15317698	USD
CY2011Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8868615	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11145229	USD
CY2012Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4732953	USD
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1170000	shares
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	1577021	shares
CY2011Q4	us-gaap	Temporary Equity Liquidation Preference Per Share TemporaryEquityLiquidationPreferencePerShare	1.00
CY2012Q2	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10582011	shares
CY2011Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10582011	shares
CY2011Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	6662748	shares
CY2012Q2	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	4311190	shares
CY2011Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	6662748	shares
CY2012Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	4311190	shares
CY2012Q2	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	3574431	USD
CY2011Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	4811326	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	111517	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	295356	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits Resulting In Net Operating Loss Carryforward UnrecognizedTaxBenefitsResultingInNetOperatingLossCarryforward	8838200	USD
CY2012Q2	nbs	Adjusted Conversion Price AdjustedConversionPrice	1.28
CY2012Q2	nbs	Annual Appropriation Percent AnnualAppropriationPercent	0.1
CY2012Q3	nbs	Bank Deposit Freeze BankDepositFreeze	50000000	USD
	nbs	Clinical Services Reimbursement ClinicalServicesReimbursement	1100000	USD
CY2012Q2	nbs	Clinical Services Reimbursement ClinicalServicesReimbursement	800000	USD
	nbs	Clinical Services Reimbursement ClinicalServicesReimbursement	2000000	USD
CY2011Q2	nbs	Clinical Services Reimbursement ClinicalServicesReimbursement	600000	USD
	nbs	Common Stock Issued To Acquire Businesses CommonStockIssuedToAcquireBusinesses	17866200	USD
	nbs	Common Stock Issued To Acquire Businesses CommonStockIssuedToAcquireBusinesses	0	USD
CY2012Q2	nbs	Common Stock Returned CommonStockReturned	1040000	shares
CY2012Q2	nbs	Concentration Risk Percentage Total Accounts Payable ConcentrationRiskPercentageTotalAccountsPayable	0.281
	nbs	Dividend On Preferred Stock Shares Of Common Stock Issuable DividendOnPreferredStockSharesOfCommonStockIssuable	130700	USD
	nbs	Dividend On Preferred Stock Shares Of Common Stock Issuable DividendOnPreferredStockSharesOfCommonStockIssuable	475200	USD
CY2011Q4	nbs	In Process Rd InProcessRd	9400.0	USD
	nbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	963948	USD
	nbs	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	961572	USD
	nbs	Issuance Of Common Stock In Connection With Preferred Stock Settlement Value IssuanceOfCommonStockInConnectionWithPreferredStockSettlementValue	652167	USD
	nbs	Issuance Of Common Stock In Exchange For Convertible Preferred Stock IssuanceOfCommonStockInExchangeForConvertiblePreferredStock	1959600	USD
	nbs	Issuance Of Common Stock In Exchange For Convertible Preferred Stock IssuanceOfCommonStockInExchangeForConvertiblePreferredStock	717700	USD
CY2009Q4	nbs	Percentage Of Additional Paid In Capital PercentageOfAdditionalPaidInCapital	0.45
CY2009Q4	nbs	Percentage Of Distributed Profit PercentageOfDistributedProfit	0.06
CY2012Q2	nbs	Percentage Of Registered Capital PercentageOfRegisteredCapital	0.5
CY2009Q4	nbs	Percentage Of Undistributed Profit PercentageOfUndistributedProfit	0.49
CY2010Q4	nbs	Preferred Offering Units PreferredOfferingUnits	10582011	shares
CY2012Q2	nbs	Preferred Stock Conversion Conversion Price Per Share PreferredStockConversionConversionPricePerShare	2.00
CY2012Q2	nbs	Preferred Stock Pre Payment Minimum Increment Value PreferredStockPrePaymentMinimumIncrementValue	1000000	USD
CY2011Q4	nbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
CY2012Q2	nbs	Preferred Stock Shares Designated PreferredStockSharesDesignated	825000	shares
	nbs	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	23395	USD
	nbs	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	-233800	USD
CY2012Q2	nbs	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	640000	shares
	nbs	Supplemental Dividends From Subsidiaries SupplementalDividendsFromSubsidiaries	0	USD
	nbs	Supplemental Dividends From Subsidiaries SupplementalDividendsFromSubsidiaries	11726000	USD
	nbs	Supplemental Property And Equipment Net SupplementalPropertyAndEquipmentNet	0	USD
	nbs	Supplemental Property And Equipment Net SupplementalPropertyAndEquipmentNet	1283400	USD
CY2012Q2	nbs	Warrants Exercise Price WarrantsExercisePrice	0.51
	nbs	Weightedaveragenumberbasicdilutedsharesoutstanding Weightedaveragenumberbasicdilutedsharesoutstanding	77117905	shares
CY2011Q2	nbs	Weightedaveragenumberbasicdilutedsharesoutstanding Weightedaveragenumberbasicdilutedsharesoutstanding	80567011	shares
	nbs	Weightedaveragenumberbasicdilutedsharesoutstanding Weightedaveragenumberbasicdilutedsharesoutstanding	123109487	shares
CY2012Q2	nbs	Weightedaveragenumberbasicdilutedsharesoutstanding Weightedaveragenumberbasicdilutedsharesoutstanding	134412025	shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0000320017
CY2012Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	152535118	shares
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
	dei	Document Period End Date DocumentPeriodEndDate	2012-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	NeoStem, Inc.
	dei	Local Phone Number LocalPhoneNumber	(212) 584-4180

Files In Submission

Name	View Source	Status
0001445305-12-002636-index-headers.html	Edgar Link	pending
0001445305-12-002636-index.html	Edgar Link	pending
0001445305-12-002636.txt	Edgar Link	pending
0001445305-12-002636-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
nbs-10qx20120630.htm	Edgar Link	pending
nbs-20120630.xml	Edgar Link	completed
nbs-20120630.xsd	Edgar Link	pending
nbs-20120630_cal.xml	Edgar Link	unprocessable
nbs-20120630_def.xml	Edgar Link	unprocessable
nbs-20120630_lab.xml	Edgar Link	unprocessable
nbs-20120630_pre.xml	Edgar Link	unprocessable
nbs-ex104_2012630xq2.htm	Edgar Link	pending
nbs-ex105_2012630xq2.htm	Edgar Link	pending
nbs-ex106_2012630xq2.htm	Edgar Link	pending
nbs-ex311_20120630xq2.htm	Edgar Link	pending
nbs-ex312_20120630xq2.htm	Edgar Link	pending
nbs-ex321_20120630xq2.htm	Edgar Link	pending
nbs-ex322_20120630xq2.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta

2012 Q3 Form 10-Q Financial Statement

#000144530512002636 Filed on August 14, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA LISATA THERAPEUTICS, INC. Stock $lsta

2012 Q3 Form 10-Q Financial Statement

#000144530512002636 Filed on August 14, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LSTA
LISATA THERAPEUTICS, INC. Stock $lsta